Fact checked byDrew Amorosi

Read more

October 28, 2024
2 min read
Save

Top in cardiology: New guideline for stroke prevention; oral semaglutide

Fact checked byDrew Amorosi
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new guideline on primary prevention of a first stroke from the American Heart Association and the American Stroke Association calls for increased screening of risk factors and increased attention on lifestyle counseling.

“In the U.S., there is a renewed cause for alarm because stroke has risen from the fifth leading cause of death to the fourth leading cause,” Cheryl D. Bushnell, MD, MHS, FAHA, professor and vice chair of research in the department of neurology at Wake Forest University School of Medicine and chair of the writing committee, told Healio.

Ischemic Stroke
A new guideline on primary prevention of a first stroke calls for increased screening of risk factors. Image: Adobe Stock

“Therefore, focusing on screening and identifying patients at risk, applying guideline-recommended therapies for prevention, and counseling on lifestyle are more important than ever if we want to reduce the burden of strokes in this country.”

It was the top story in cardiology last week.

In another top story, results from the phase 3 SOUL trial revealed that once-daily oral semaglutide plus standard care reduced risk for major adverse cardiovascular events among people with diabetes, cardiovascular diseaes and/or kidney disease compared with placebo plus standard care.

Read these and more top stories in cardiology below:

New stroke primary prevention guideline calls for more screening of risk factors

The new guideline on primary prevention of stroke from the American Heart Association and American Stroke Association calls for more screening of risk factors such as high BP, high cholesterol and high blood glucose. Read more.

Oral semaglutide prevents CV events in people with diabetes and heart disease, CKD

Oral semaglutide demonstrated an approximately 14% reduction in major adverse cardiovascular events compared with standard care along in patients with diabetes, cardiovascular and/or kidney disease, according to the top-line results of the phase 3 SOUL trial. Read more.

Many people with ultraprocessed food addiction not identified as needing treatment

Addiction to ultraprocessed food may be diagnosed similarly to other substance use disorders, and reducing stigma and tailored treatment are both important to improving cardiometabolic health, a speaker reported at the Cardiometabolic Health Congress. Read more.

VIDEO: Pay attention to cardiovascular risk in young adults, measure Lp(a)

In this Healio video exclusive, Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC, discusses her presentation at the Cardiometabolic Health Congress,Primary Prevention of CVD: The Sooner the Better?” Watch here.

VIDEO: Sleep physiology and risk for Alzheimer’s, obesity and cardiovascular events

In this Healio video exclusive, Virend K. Somers, MD, PhD, discusses his presentation at the Cardiometabolic Health Congress, “Sleep Disorders and Cardiometabolic Health.” Watch here.